GENELINK ENGAGES FIRST EQUITY CAPITAL SECURITIES, INC. TO PROVIDE INVESTMENT BANKING SERVICES
October 28, 2003

MARGATE, NJ – (Business Wire) –October 28, 2003 – GeneLink BioSciences, Inc. (OTCBB:GNLK) announced it has signed an agreement with First Equity Capital Securities, Inc. to provide investment banking services to the Company.

First Equity Capital Securities, Inc. ("First Equity") is an investment banking firm which provides fund raising and consulting services on a best efforts basis, specializing in growing companies. First Equity has significant experience and interest in companies involved in biosciences and, specifically, pharmacogenomics. Kenneth R. Levine, Managing Director of First Equity, said “We have been watching GeneLink for some time, and we feel that the Company has been successfully developing its intellectual assets and that GeneLink is poised to leverage its position through strategic relationships and licenses in order to enhance its revenue prospects.”

“We are very pleased to have First Equity as our investment banking partner. Their engagement will help GeneLink reach its next revenue stage,” remarks John R. DePhillipo, Chairman of GeneLink BioSciences, Inc. “First Equity has already procured financing for GeneLink which has helped the Company advance its scientific research projects and patent procurements. In addition, First Equity is assisting the Company in moving forward with prospective licensees of GeneLink’s proprietary technologies.”

GeneLink BioSciences, Inc., a pioneer DNA banking and hereditary genetic information service, has developed a proprietary method for genetic assessments (patents pending) and is beginning to license its breakthrough Nutragenetic and Dermagenetic Profile Assessments™ to companies that market or manufacture products for the $100 billion plus skin care, nutritional supplement, and health care industries. For more information about GeneLink, visit its website at www.genelink.info.

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.